https://ijmri.de/index.php/jmsi
volume 4, issue 6, 2025
336
HELICOBACTER PYLORI AND GASTRIC CANCER: PROSPECTS OF A
PERSONALIZED APPROACH
Azimjon Yo‘ldoshev Zafarjon ugli
Kokand University, Andijan Branch, Medical Faculty
[ Contact:
]
Abstract:
This scientific thesis thoroughly examines the pathological changes induced by
Helicobacter pylori infection in the gastric mucosa, including their clinical manifestations,
morphological stages, and its role in the development of gastric cancer. Modern diagnostic
methods—both invasive and non-invasive—are discussed in detail, alongside effective treatment
strategies such as bismuth-based quadruple therapy, combination antibiotic regimens, and
adjunctive probiotic use. The scientific and practical relevance of this work lies in the fact that
early detection and treatment of H. pylori infection play a crucial role in preventing gastric
cancer among the population.
Keywords:
Helicobacter pylori, chronic gastritis, intestinal metaplasia, glandular atrophy,
gastric cancer, CagA, VacA, p53 mutation, dysplasia, epigenetic changes, modern therapy,
urease enzyme, probiotics, inflammatory mediators, non-invasive diagnostics.
Relevance of the Topic:
Helicobacter pylori is a microaerophilic, Gram-negative, spiral-shaped
bacterium that colonizes the human gastric mucosa. Due to long-term colonization, it leads to
various degrees of gastrointestinal pathologies, especially chronic gastritis, peptic ulcer disease,
metaplasia, and gastric cancer. According to the World Health Organization (WHO), more than
50% of the global population is infected with H. pylori [5]. Each year, nearly 1 million new cases
of gastric cancer are diagnosed worldwide, with approximately 700,000 related deaths. Gastric
cancer ranks third among cancers in terms of mortality. H. pylori predominantly localizes in the
antral and corpus regions of the stomach and initiates inflammation of the mucosal layer [2]. The
virulence factors of the bacterium—CagA (cytotoxin-associated gene A), VacA (vacuolating
cytotoxin A), oipA, and babA—directly damage epithelial cells. Furthermore, the urease enzyme
produced by H. pylori hydrolyzes urea into ammonia, altering the gastric juice pH and
weakening the mucosal defense, ultimately triggering chronic inflammation. Morphologically,
chronic gastritis is characterized by lymphocytic infiltration, epithelial dystrophy, lamina propria
infiltration with granulocytes, and finally glandular atrophy [1]. Clinically, the infection presents
with dyspeptic symptoms such as nausea, bloating, abdominal pain, chronic fatigue, and
sometimes anemia.
Precancerous Stages: Atrophy and Intestinal Metaplasia
Prolonged H. pylori infection results in glandular atrophy of the gastric mucosa, which paves the
way for intestinal metaplasia—a transformation of the gastric epithelium into intestinal-type
epithelium, often marked by the appearance of Goblet cells. This condition is regarded as
premalignant. Intestinal metaplasia is typically accompanied by genetic and epigenetic
alterations, including mutations of the p53 gene, reduced E-cadherin expression, and changes in
DNA methylation, all of which contribute to the initiation of carcinogenesis [3].
https://ijmri.de/index.php/jmsi
volume 4, issue 6, 2025
337
Pathogenesis of Gastric Cancer
Gastric adenocarcinoma associated with H. pylori infection predominantly belongs to the
intestinal type according to the Lauren classification [4]. The classical sequence in this model
follows:
Gastritis → Atrophy → Intestinal Metaplasia → Dysplasia → Carcinoma.
Several pathological mechanisms are involved in this process: Cytokines and Inflammatory
Mediators: Activation of Interleukin-1β, TNF-α, and NF-κB increases epithelial cell proliferation.
Genetic Alterations: Silencing or methylation of the CDH1 gene, inactivation of the APC gene,
and mutations in p53. Mitochondrial Stress: Reactive oxygen species (ROS) produced by H.
pylori damage cellular DNA. Epidemiological studies have confirmed that H. pylori infection is
a major risk factor for the development of gastric cancer. Consequently, the WHO has classified
this bacterium as a Class I carcinogen.
Modern Diagnostic and Treatment Approaches
Currently, H. pylori infection is diagnosed using the following methods: Invasive Methods:
Endoscopic biopsy + histology, rapid urease test (CLO test), bacterial culture, and urea breath
test. Non-Invasive Methods: Serological testing, urea breath test, and stool antigen detection.
Treatment protocols are continually updated to improve eradication rates. First-line therapy
typically includes: Bismuth-based Quadruple Therapy: Bismuth subcitrate + metronidazole +
tetracycline + proton pump inhibitor (PPI) [6]. Combination with New-Generation Antibiotics:
Regimens based on clarithromycin, levofloxacin, or rifabutin. Probiotics: Adjunctive use of
probiotics has been shown to improve the effectiveness of H. pylori eradication.
Conclusion
Helicobacter pylori is a microorganism with a strong pathogenic link between chronic gastritis
and gastric cancer. Early detection and effective eradication of this infection constitute critical
components in the prevention of gastric cancer. In clinical practice, emphasis should be placed
on accurate diagnosis, treatment, and post-eradication monitoring of H. pylori infection.
Furthermore, combining standard treatment with probiotics may significantly enhance
therapeutic outcomes.
References:
1. Yo‘ldoshev T.T., Egamova S.T. Pathogenesis and Clinical Presentation of Diseases. —
Tashkent: Tibbiyot Publishing, 2020. — 480 pages.
2. Azizov A.A., Teshaboyev B.Yu. Gastroenterology: Clinical and Practical Guide. — Tashkent:
Ilm Ziyo, 2021. — 356 pages.
3. Sattorov O‘.X., Abdurahmonova R.A. Molecular Biology and Genetics. — Tashkent: Fan va
texnologiya, 2019. — 400 pages.
4. Bobojonov E.T. Fundamentals of Modern Oncology. — Tashkent: Tibbiyot, 2022. — 300
pages.
5. World Health Organization (WHO). Helicobacter pylori and Gastric Cancer.
https://www.who.int
6. Mayo Clinic. Helicobacter pylori (H. pylori) Infection – Diagnosis and Treatment.
https://www.mayoclinic.org
